A clinical trial to assess a potential treatment option for multiple myeloma

The MagnetisMM-7 study is a phase 3 clinical trial looking for around 660 participants with newly diagnosed multiple myeloma following autologous stem cell transplant (ASCT). The study is designed to assess whether the study medicine can provide clinical benefit when compared to the current standard of care therapy.

Who may participate

Participating in a clinical study is an important and personal decision. Thank you for considering the MagnetisMM-7 study.

This study may be an option for men and women who:

  • Are at least 18 years old
  • Have newly diagnosed multiple myeloma after undergoing ASCT
  • Have not had previous maintenance treatment for multiple myeloma

There are other requirements for taking part in this study. We will explain these to you if you’d like to learn more.

If you’re interested in participating, you will review and sign an informed consent document and visit the study doctor’s office during a screening process to see whether you meet the eligibility criteria and are able to take part.


Multiple myeloma


18+ years


Male or Female

Each clinical study has its own guidelines for who can participate, called eligibility criteria. However, only the research study staff can determine if you qualify to enroll in the study.

What to expect

Participants will be randomly (by chance) assigned to one of two treatment ‘Arms’.

Arm B will take the comparator medicine as oral capsules every day and will have 1 visit every 1 or 2 weeks for 3 months, followed by 1 visit every 4 weeks.

Arm C will receive the investigational medicine at hospital as an injection under the skin and have visits fortnightly for 13-18 months (depending on how their disease responds to the study treatment), then every 4 weeks. Overnight hospitalization is required for the first 2 injections.

The study team will assess your health, safety and the effectiveness of the study medicines.

After a final visit about a month after your last dose, you will have phone calls every 3 months or clinic visits every month until disease progression, to check on your health. More follow-up visits may be required, depending on your disease.

Length of study treatment

Depending on the number of cycles, this could last approximately 7 years

Number of study visits

1-4 visits per 28-day cycle, until end of study treatment

Long-term follow up

1 call or visit at least every 3 months

About the study medicine

An older couple walking down a tranquil looking countryside path. – Pfizer Clinical Trials
An older couple walking down a tranquil looking countryside path. – Pfizer Clinical Trials

About the study medicine

We are studying if elranatamab (the study medicine) is safe and effective for people newly diagnosed with multiple myeloma after undergoing autologous stem-cell transplantation (ASCT).

Elranatamab is given as a shot under the skin (subcutaneous injection) – not through an IV infusion – and is administered by a trained medical professional.

Potential benefits and risks of taking part in the MagnetisMM-7 study

People who take part in clinical studies are key to advancing medical research. By taking part in the MagnetisMM-7 study, you will be aiding medical research which may help others with multiple myeloma in the future.

Over the course of the study, a participant’s health may get better, get worse, or stay the same. People who are considering taking part in the study will be given a complete list of risks and possible discomforts before agreeing to participate. As with any medication, there may be a reaction to the study medicine.

Frequently asked questions

What is multiple myeloma?

Multiple myeloma is a type of blood cancer that forms in bone marrow. Healthy bone marrow produces plasma cells, which make antibodies to fight infection. But in multiple myeloma, plasma cells become cancerous. These cancer cells can crowd out normal blood cells, forming tumors and leaving a person vulnerable to infection.

Is this helpful?
How does this study drug work?
The study drug is thought to work by connecting certain immune system cells, known as T-cells, to myeloma cells (cancer cells). Connecting these cells activates the immune cells, potentially killing the myeloma cells.
Is this helpful?
What is Informed Consent?

Informed consent is one of the most important tools to help you understand how your rights, safety, and well-being will be addressed throughout the trial.

During the informed consent discussion, you will be given all details about the study, including potential benefits and risks of taking part. You will also be given a document summarizing this information, which you will sign to confirm that you would like to take part in the clinical trial.

Is this helpful?
Is taking part in this clinical trial voluntary?
Yes, participation in clinical trials is completely voluntary: taking part in a trial is your choice. You are free to stop being in this trial at any time and for any reason and it will not affect your future medical care in any way.
Is this helpful?
Why do we need clinical trials?

Clinical trials are important to understand more about potential treatment options for all sorts of conditions. Clinical research studies also help us learn more about the side effects of a potential treatment and to understand whether the possible benefits outweigh the risks.

Is this helpful?
Will I have to pay to be in the study? Will my insurance cover the cost?

The study medicine and all study-related care and procedures are provided at no cost. You don’t need health insurance to join a clinical study. However, you (or your health insurance provider) may be responsible for medical expenses that are part of your usual healthcare. Talk with your study team or review the informed consent document to find out exactly what is covered.

Is this helpful?
Is there travel support available for participants in this study?
Travel to the study center and other expenses (such as meals) may be covered. Please discuss the details with your study team.
Is this helpful?
Will my personal information be kept private?
Your health information and any data that could be used to identify you (such as immigration status) will be kept private and safe. Only information that relates to the study will be collected, and only your study team, study doctor, and organizations that oversee the study will be able to access it. Your personal information won’t be shared with third parties such as the government or advertisers.
Is this helpful?
What will happen to my personal information after the study ends?
Some of the information collected on devices will be kept for up to 25 years. All other records will be deleted after 15 years.
Is this helpful?
Learn more
View locations for this study

    Continue exploring

    How clinical trials work

    Steps to join a clinical trial

    Protecting your safety & privacy